Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207051201> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4207051201 endingPage "i486" @default.
- W4207051201 startingPage "i486" @default.
- W4207051201 abstract "Abstract Background Multiple adalimumab (ADA) biosimilars are now available since they were first commercialized in 2019 after having proved their safety and effectiveness in rheumatoid diseases. However, real data in inflammatory bowel disease (IBD) remain scarce. The main aim was to evaluate the remission rates after switching from ADA originator (Humira) to biosimilar (Hyrimoz) in a cohort of patients in remission at time of inclusion as well as to describe any safety issues. Methods We performed a prospective, observational cohort in a tertiary IBD referral centre. All patients on Humira who were in clinical remission (defined as Harvey-Bradshaw score ≤4 or partial Mayo score ≤2) +/- biological remission (faecal calprotectin <250 μg/gr and C-reactive protein [CRP] <5gr/L) +/- endoscopic/radiologic remission at time of switch were included and followed-up for at least 9 months. Data on IBD phenotype, CRP, ADA drug and antibody levels and faecal calprotectin were collected. Results A total of 40 patients were included, 53.7% (22) men. Median follow-up 10.6 months (IQR 10–11.1). Regarding IBD type, 85.4% (35) suffered from Crohn′s disease (CD) and 14.6% (6) from ulcerative colitis (UC). Table 1 shows the baseline characteristics of patients. Prior to switch, adalimumab levels were 7.7 mg/mL (5.9–11.2), CRP 0.4 (0–1.7) gr/L and faecal calprotectin 140 μg/gr (69–180). One patient stopped the drug (2.5%) as per personal reasons and 5% (2) flared during the follow-up but no drug cessation was needed. At the end of follow-up 94.9% (37) patients remained in clinical remission. No severe adverse events were reported. Statistical differences were found in ADA levels prior and after switching (7.7 vs 5.9 mg/mL, p=0.001), CRP levels (0.4 vs 0.7 g/L; p=0.016) and albumin levels (4.4 vs 4.6 g/L, p=0.015). Conclusion Switching from Humira to Adalimumab biosimilar appeared to be effective and safe with most patients being in clinical remission at the end of follow-up. Statistical differences were found in adalimumab levels, CRP after switching and albumin, however, the impact of these differences was not noticeable." @default.
- W4207051201 created "2022-01-26" @default.
- W4207051201 creator A5022739135 @default.
- W4207051201 creator A5047679893 @default.
- W4207051201 creator A5058402704 @default.
- W4207051201 creator A5060038685 @default.
- W4207051201 creator A5060646780 @default.
- W4207051201 creator A5089237494 @default.
- W4207051201 date "2022-01-01" @default.
- W4207051201 modified "2023-09-27" @default.
- W4207051201 title "P534 Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission" @default.
- W4207051201 doi "https://doi.org/10.1093/ecco-jcc/jjab232.661" @default.
- W4207051201 hasPublicationYear "2022" @default.
- W4207051201 type Work @default.
- W4207051201 citedByCount "0" @default.
- W4207051201 crossrefType "journal-article" @default.
- W4207051201 hasAuthorship W4207051201A5022739135 @default.
- W4207051201 hasAuthorship W4207051201A5047679893 @default.
- W4207051201 hasAuthorship W4207051201A5058402704 @default.
- W4207051201 hasAuthorship W4207051201A5060038685 @default.
- W4207051201 hasAuthorship W4207051201A5060646780 @default.
- W4207051201 hasAuthorship W4207051201A5089237494 @default.
- W4207051201 hasBestOaLocation W42070512011 @default.
- W4207051201 hasConcept C126322002 @default.
- W4207051201 hasConcept C2777138892 @default.
- W4207051201 hasConcept C2777575956 @default.
- W4207051201 hasConcept C2778260677 @default.
- W4207051201 hasConcept C2778292693 @default.
- W4207051201 hasConcept C2779008522 @default.
- W4207051201 hasConcept C2779134260 @default.
- W4207051201 hasConcept C2780132546 @default.
- W4207051201 hasConcept C2780479503 @default.
- W4207051201 hasConcept C59491497 @default.
- W4207051201 hasConcept C71924100 @default.
- W4207051201 hasConcept C72563966 @default.
- W4207051201 hasConcept C90924648 @default.
- W4207051201 hasConceptScore W4207051201C126322002 @default.
- W4207051201 hasConceptScore W4207051201C2777138892 @default.
- W4207051201 hasConceptScore W4207051201C2777575956 @default.
- W4207051201 hasConceptScore W4207051201C2778260677 @default.
- W4207051201 hasConceptScore W4207051201C2778292693 @default.
- W4207051201 hasConceptScore W4207051201C2779008522 @default.
- W4207051201 hasConceptScore W4207051201C2779134260 @default.
- W4207051201 hasConceptScore W4207051201C2780132546 @default.
- W4207051201 hasConceptScore W4207051201C2780479503 @default.
- W4207051201 hasConceptScore W4207051201C59491497 @default.
- W4207051201 hasConceptScore W4207051201C71924100 @default.
- W4207051201 hasConceptScore W4207051201C72563966 @default.
- W4207051201 hasConceptScore W4207051201C90924648 @default.
- W4207051201 hasIssue "Supplement_1" @default.
- W4207051201 hasLocation W42070512011 @default.
- W4207051201 hasOpenAccess W4207051201 @default.
- W4207051201 hasPrimaryLocation W42070512011 @default.
- W4207051201 hasRelatedWork W1556902742 @default.
- W4207051201 hasRelatedWork W2034375951 @default.
- W4207051201 hasRelatedWork W2090228779 @default.
- W4207051201 hasRelatedWork W2187503363 @default.
- W4207051201 hasRelatedWork W2512358714 @default.
- W4207051201 hasRelatedWork W2896737472 @default.
- W4207051201 hasRelatedWork W2984572983 @default.
- W4207051201 hasRelatedWork W3026688063 @default.
- W4207051201 hasRelatedWork W3137747906 @default.
- W4207051201 hasRelatedWork W4323351148 @default.
- W4207051201 hasVolume "16" @default.
- W4207051201 isParatext "false" @default.
- W4207051201 isRetracted "false" @default.
- W4207051201 workType "article" @default.